GLP-1 before-and-afters on TikTok: what the results don't tell you

What did @americanhealthinstitute actually say?

Almost nothing, technically. The entire spoken transcript is: "She's working on three things right now. Her self, her life, her happiness. She is me." That's it. Paired with hashtags like #tirzepatideweightloss and #mounjarojourney, and a caption celebrating patient results, the video is a before-and-after promotional post dressed in inspirational language. The actual medical claim isn't spoken out loud. It's implied through visual framing and hashtag context: that GLP-1 medications like tirzepatide or semaglutide produced the transformation shown. That's a meaningful distinction, because implied medical claims carry the same regulatory weight as stated ones, and the audience at 380,000 views is clearly receiving a weight-loss drug advertisement, whether or not the words are ever spoken.

Does the science back this up?

The general premise, that GLP-1 receptor agonists produce significant weight loss, is well-supported. But the video implies more than that. Before-and-after content implies the results are typical, reproducible, and primarily attributable to the drug. None of those implications are straightforward.

The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed tirzepatide at the highest dose produced a mean weight reduction of 20.9% over 72 weeks in adults with obesity. That's real. The STEP 1 trial (Wilding et al., 2021, NEJM) showed semaglutide 2.4mg produced about 14.9% mean body weight reduction. Also real. But "mean" hides a lot. Some patients lose dramatically more. Some lose far less. Individual before-and-after results are, by definition, selected, not average.

The hashtag #ivtherapy also appears in the caption, which raises a separate concern. IV therapy is not a component of GLP-1 treatment protocols supported by clinical evidence for weight loss. Its inclusion without explanation muddles what's actually being credited for the result shown.

What did they get wrong (or right)?

They didn't technically get the science wrong, because they didn't state any science. That's the problem. The video functions as a testimonial-style advertisement for GLP-1 weight loss services at a telehealth platform, but it uses emotional language and hashtag targeting to imply clinical outcomes without making a single verifiable claim. That's not a fact-check win. That's a compliance gray zone.

The FDA has specific guidance on drug promotion and testimonials. Using a patient transformation alongside drug-related hashtags, without fair balance disclosures about side effects, contraindications, or result variability, raises real questions under 21 CFR Part 202. A regulated telehealth platform should know better.

What they got right: GLP-1 medications do produce meaningful weight loss in many patients. The emotional framing of weight loss as connected to self-image and quality of life reflects real patient experience documented in outcomes research (Warkentin et al., 2014, Obesity Reviews). But emotion doesn't substitute for disclosure.

What should you actually know?

Before-and-after content is the oldest trick in weight loss marketing. The fact that it now involves legitimate, FDA-approved medications doesn't make the format more honest. Here's what that video won't tell you.

• GLP-1 side effects are common and sometimes serious. Nausea affects up to 44% of tirzepatide users in trials (Jastreboff et al., 2022). Pancreatitis, though rare, is a documented risk.
• Weight regain after stopping GLP-1 medications is substantial. Wilding et al. (2022, Diabetes, Obesity and Metabolism) showed participants regained two-thirds of lost weight within a year of discontinuing semaglutide.
• Compounded semaglutide and tirzepatide, widely used by telehealth platforms, are not equivalent to brand-name Ozempic, Wegovy, Mounjaro, or Zepbound. The FDA has stated explicitly that compounded versions are not FDA-approved and carry additional uncertainty.
• The #ivtherapy hashtag is unexplained. There is no peer-reviewed evidence that IV therapy meaningfully enhances GLP-1 outcomes.
• Individual results vary significantly. Showing one patient's transformation without stating that results are not typical is a classic misleading advertising pattern.